Deoxycoformycin in the treatment of patients with hairy cell leukemia : Results of a Spanish collaborative study of 80 patients

• Published in: Cancer Vol. 88; no. 2; pp. 352 - 357
• Main Authors: RAFEL, M, CERVANTES, F, BELTRAN, J. M, ZUAZU, F, HERNANDEZ, L. NIETO, RAYON, C, TALAVERA, J. G, MONTSERRAT, E
• Format: Journal Article
• Language: English
• Published: New York, NY Wiley-Liss 15.01.2000
• Subjects: Aged; Antibiotics, Antineoplastic - adverse effects; Antibiotics, Antineoplastic - therapeutic use; Antineoplastic agents; Biological and medical sciences; Chemotherapy; Disease-Free Survival; Female; Humans; Leukemia, Hairy Cell - drug therapy; Leukemia, Hairy Cell - pathology; Male; Medical sciences; Middle Aged; Pentostatin - adverse effects; Pentostatin - therapeutic use; Pharmacology. Drug treatments; Recurrence; Treatment Outcome; Antineoplastic agent; Human; Prognosis; Enzyme; Toxicity; Treatment efficiency; Enzyme inhibitor; Malignant hemopathy; Adenosine deaminase; Pentostatin; Chemotherapy; Chronic; Hairy cell leukemia; Treatment; Lymphoproliferative syndrome; Hydrolases; Complication; Purine; Antagonist
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/(SICI)1097-0142(20000115)88:2<352::AID-CNCR15>3.0.CO;2-8

Deoxycoformycin (DCF) has been reported to produce high response rates in patients with hairy cell leukemia (HCL), but to the authors' knowledge data regarding experience with such therapy in a large HCL series are scarce. Between 1988-1997, DCF (4 mg/m(2)/day, every 2 weeks) was administered to 80 HCL patients in 32 Spanish institutions. In 35 of 78 evaluable patients DCF was the first-line therapy; the remaining 43 patients had received other therapies. Pretreatment variables influencing the achievement of complete remission (CR) and event free survival were identified by multivariate analyses. The median number of cycles administered was 7 (range, 1-22 cycles). A CR was obtained in 56 patients (72%) and a partial remission was obtained in 13 patients, for an overall response rate of 88%. In the multivariate analysis previous splenectomy and an Eastern Cooperative Oncology Group (ECOG) performance status > or = 2 were the parameters adversely influencing CR achievement. With a median follow-up of 31.2 months (range, 0.4-126.5 months), disease recurrence was observed in 11 of the CR patients, 5 of whom showed a further response to DCF. An ECOG performance status > or = 2 was the only pretreatment variable associated with a shorter event free survival. Seven patients died, four during the treatment period. The actuarial median event free survival was 46 months (95% confidence interval, 22.5-69.5 months), and 48.7% of the 56 patients who achieved a CR were expected to be alive and disease free at 5 years. Hematologic toxicity (marked neutropenia [22 cases], anemia [6 cases], and thrombocytopenia [1 case]) was the main side effect, followed by nausea and emesis (5 cases); 14 patients required hospitalization. The results of the current study confirm the effectiveness and acceptable toxicity of DCF in the treatment of patients with HCL.